Insufficient immunosuppressive treatment in patients with myasthenia gravis in the context of the possibility of new therapies - a single center experience
{{output}}
Aim of the study: The authors aimed to characterize the population with myasthenia gravis (MG), focusing on their eligibility for a therapeutic program with terminal complement protein C5 inhibition (ravulizumab), neonatal Fc rec... ...
